Glycosylated and non-glycosylated recombinant human granulocyte colony- stimulating factor (rhG-CSF) - What is the difference?

Medical Oncology

Volumn 15, Issue 4, 1998, Pages 229-233

  Höglund, Martin ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Comparative study; Filgrastim; G CSF; Glycosylation; Lenograstim

Indexed keywords

CD34 ANTIGEN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

BIOEQUIVALENCE; BONE PAIN; BREAST CANCER; CHO CELL; CLINICAL TRIAL; COLONY FORMATION; COLONY FORMING UNIT GM; DRUG POTENCY; DRUG STRUCTURE; ESCHERICHIA COLI; HUMAN; MOLECULAR WEIGHT; NEUTROPENIA; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; REVIEW; STEM CELL; STRUCTURE ACTIVITY RELATION; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032465272     PISSN: 07360118     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02787205     Document Type: Review

References (48)

1. Asano S. Human granulocyte colony-stimulating factor: its basic aspects and clinical applications. Am J Pediatr Hematol Oncol 1991; 13: 400-413.
2. Demetri GD, Griffin JD. Granulocyte colony-stimulating factor and its receptor. Blood 1991; 78: 2791-2808.
3. Souza L et al. Recombinant human granulocyte colony-stimulating factor: Effects on normal and leukemic myeloid cells. Science 1986; 232: 61.
4. Nagata S et al. Molecular cloning and expression of cDNA for human granulocyte colony-stimulating factor. Nature 1986; 319: 415-418.
5. Welte K, Gabrilove J, Bronchud MH, Platzer E, Morstyn G. Filgrastim (r-metHuG-CSF): the first 10 years. Blood 1996; 88: 1907-1929.
6. To LB, Haylock DN, Simmons PJ, Juttner CA. The biology and clinical uses of blood stem cells. Blood 1997; 89: 2233-2258.
7. - cells by glycosylated and nonglycosylated G-CSF in healthy volunteers - a comparative study. Eur J Haematol 1997; 59: 177-183.
8. Watts MJ, Addison I, Long SG, Hartley S, Warrington S, Boyce M, Linch DC. Crossover study of the haematological effects and pharmacokinetics of glycosylated and non-glycosylated G-CSF in healthy volunteers. Br J Haematol 1997; 98: 474-479.
9. de Arriba F et al. Prospective randomized study comparing the efficacy of bioequivalent doses of glycosylated and nonglycosylated rG-CSF for mobilizing peripheral blood progenitor cells. Br J Haematol 1997; 96: 418-420.
10. Linch DC et al. Randomised vehicle-controlled dose finding study of glycosylated recombinant human granulocyte colony-stimulating factor after bone marrow transplantation. Bone Marrow Transplant 1993; 11: 307-311.
11. Weaver CH et al. Mobilization and harvesting of peripheral blood stem cells: randomised evaluations of different doses of filgrastim. Br J Haematol 1998; 100: 338-347.
12. + progenitor cells in high risk breast cancer patients: higher yield by splitting the dose. Blood 1997; 90(suppl 1): 592a.
13. Metcalf D. The colony stimulating factors. Cancer 1990; 65: 2185-2195.
14. Kolvenbach CG, Langley KE, Strickland TW, Kenney WC, Arakawa T. Densimetric determination of carbohydrate content in glycoproteins. J Biochem Biophys Meth 1991; 23: 295-300.
15. Wang C, Eufemi M, Turano C, Giartosio A. Influence of the carbohydrate moiety on the stability of glycoproteins. Biochemistry 1996; 35: 7299-7307.
16. Fukuda MN, Sasaki H, Lopez L, Fukuda M. Survival of recombinant erythropoietin in the circulation: the role of carbohydrates. Blood 1989; 73: 84-89.
17. Hovgaard D, Mortensen BT, Schifter S, Nissen NI. Comparative pharmacokinetics of single-dose administration of mammalian and bacterially-derived recombinant human granulocyte-macrophage colony-stimulating factor. Eur J Haematol 1993; 50: 32-36.
18. Cebon J et al. Granulocyte-macrophage colony stimulating factor from human lymphocytes. The effect of glycosylation on receptor binding and biological activity. J Biol Chem 1990; 265: 4483-4491.
19. Gribben JG et al. Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF [see comments]. Lancet 1990; 335: 434-437.
20. Ragnhammar P et al. Induction of anti-recombinant human granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived) antibodies and clinical effects in nonimmuno-compromised patients. Blood 1994; 84: 4078-4087.
21. Moonen P, Mermod JJ, Ernst JF, Hirschi M, DeLamarter JF. Increased biological activity of deglycosylated recombinant human granulocyte/macrophage colony-stimulating factor produced by yeast or animal cells. Proc Natl Acad Sci USA 1987; 84: 4428-4431.
22. Kubota N et al. Structural characterization of natural and recombinant human granulocyte colony-stimulating factors. J Biochem (Tokyo) 1990; 107: 486-492.
23. Arakawa T, Prestrelski SJ, Narhi LO, Boone TC, Kenney WC. Cysteine 17 of recombinant human granulocyte-colony stimulating factor is partially solvent-exposed. J Protein Chem 1993; 12: 525-531.
24. Hill CP, Osslund TD, Eisenberg D. The structure of granulocyte-colony-stimulating factor and its relationship to other growth factors. Proc Natl Acad Sci USA 1993; 90: 5167-5171.
25. Oh-eda M, Hase S, Ono M, Ikenaka T. Structures of the sugar chains of recombinant human granulocyte-colony-stimulating factor produced by Chinese hamster ovary cells. J Biochem (Tokyo) 1988; 103: 544-546.
26. Christi L, Clogston CL, Hu S, Boone TC, Lu HS. Glycosidase digestion, electrophoresis and Chromato-graphic analysis of recombinant human granulocyte colony-stimulating factor glycoforms produced in Chinese hamster ovary cells. J Chromatogr 1993; 637: 55-62.
27. Oh-eda M et al. Preparation of pyridylaminated O-linked sugar chains from glycoproteins blotted on a polyvinylidene difluoride membrane and application to human granulocyte colony-stimulating factor. Analytical Biochemistry 1996; 236: 369-371.
28. Nissen C, Dalle-Carbonare Y, Moser Y. In vitro comparison of the biological potency of glycosylated versus non-glycosylated rG-CSF. Drug Invest 1994; 7: 346-352.
29. Stute N et al. Pharmacokinetics of subcutaneous recombinant human granulocyte colony-stimulating factor in children. Blood 1992; 79: 2849-2854.
30. Pedrazzoli P et al. Effects of glycosylated and non-glycosylated G-CSFs, alone and in combination with other cytokines, on the growth of human progenitor cells. Anticancer Res 1996; 16: 1781-1785.
31. Decleva E, Cramer R, Zabucchi G. Glycosylation improves the priming effect exerted by recombinant human granulocyte colony-stimulating factor (lenograstim) on human neutrophil superoxide production. Int J Tissue React 1995; 17: 191-198.
32. Mire-Sluis AR, Das RG, Thorpe R. The international standard for granulocyte colony stimulating factor (G-CSF). Evaluation in an international collaborative study. J Immunol Methods 1995; 179: 117-126.
33. Okabe M et al. In vitro and in vivo hematopoietic effect of mutant human granulocyte colony-stimulating factor. Blood 1990; 75: 1788-1793.
34. Gisselbrecht C et al. A phase III randomised placebo-controlled study of lenograstim (glycosylated rHu-G-CSF) in 315 paediatric and adult autologous or allogeneic bone marrow transplant patients. Lancet 1994; 343: 696.
35. Tanaka H et al. Three types of recombinant human granulocyte colony-stimulating factor have equivalent biological activities in monkeys. Cytokine 1997; 9: 360-369.
36. Nohynek GJ, Plard JP, Wells MY. Zerial A, Roquet F. Comparison of the potency of glycosylated and non-glycosylated recombinant human granulocyte colony-stimulating factors in neutropenic and non-neutropenic CD rats. Cancer Chemother Pharmacol 1997; 39: 259-266.
37. Roberts AW et al. Broad inter-individual variations in circulating progenitor cell numbers induced by granulocyte colony-stimulating factor therapy. Stem Cells 1995; 13: 512-516.
38. + cell counts on the collection of peripheral blood stem cells. Transfusion 1996; 36: 601.
39. Denzlinger C et al. Differential activation of the endogenous leukotriene biosynthesis by two different preparations of granulocyte-macrophage colony-stimulating factor in healthy volunteers. Blood 1993; 81: 2007-2013.
40. Bonilla MA et al. Long-term safety of treatment with recombinant human granulocyte colony-stimulating factor (r-metHuG-CSF) in patients with severe congenital neutropenias. Br J Haematol 1994; 88: 723-730.
41. Donadieu J et al. A European phase II study of recombinant human granulocyte colony-stimulating factor (lenograstim) in the treatment of severe chronic neutropenia in children. Eur J Pediatr 1997; 156: 693-700.
42. Oh-Eda M et al. O-linked sugar chain of human granulocyte colony-stimulating factor protects against polymerization and denaturation allowing it to retain its biological activity. J Biol Chem 1990; 265: 11432-11435.
43. Kishita M et al. Stability of G-CSF in serum. Clin Rep 1992; 26: 1-4.
44. Mire-Sluis AR. Activity on cell lines: Stability of rG-CSFs in human serum. Int J Hematol 1996; 64: S11-S12.
45. Gervais V, Zerial A, Oschkinat H. NMR investigations of the role of the sugar moiety in glycosylated recombinant human granulocyte-colony-stimulating factor. Eur J Biochem 1997; 247: 386-395.
46. Höglund M, Smedmyr B, Simonsson B, Tötterman T, Bengtsson M. Dose-dependent mobilisation of haematopoietic progenitor cells in healthy volunteers receiving glycosylated rHuG-CSF. Bone Marrow Transplant 1996; 18: 19-27.
47. Kulkarni S et al. Comparison of equal doses of lenograstim and filgrastim for mobilization of blood stem cells in patients with hematologic malignancies. Blood 1997; 90 (suppl 1): 4226a.
48. Saccardi R, Avanci G, Bezzini R. Mobilization of PBSC for hematological rescue: comparison between glycosylated and non-glycosylated G-CSF. Bone Marrow Transplant 1997; 19 (Suppl. 1): S11.